利德曼：预计2025年净利润亏损1500万元–2800万元

Core Viewpoint - The company expects a net loss of 15 million to 28 million yuan for the fiscal year 2025, compared to a loss of 75.1013 million yuan in the same period last year [1] Group 1: Financial Performance - The anticipated impact of non-recurring gains and losses on net profit is approximately 9 million yuan, while the previous year's impact was 22.37 million yuan [1] - The company's main business revenue and gross margin of diagnostic reagent products have decreased year-on-year due to the expansion of domestic diagnostic reagent centralized procurement, further implementation of DRG/DIP policies, and intensified industry competition [1] Group 2: Industry Context - The industry is facing increased competition, which has contributed to the decline in the company's main business revenue and gross margin [1]